Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

BTIG Research assumed coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research report released on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) will likely be releasing its earnings data after the market closes on ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation ...

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100 ...

As of April 2, 2025, the average one-year price target for NRx Pharmaceuticals is $32.30/share. The forecasts range from a low of $19.19 to a high of $47.25. The average price target represents an ...

WILMINGTON, Del., March 17, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company ...